文献速递临床免疫临床生化

三种免疫分析平台检测血浆GFAP在阿尔茨海默病中的分析与临床性能比较

Comparison of the analytical and clinical performance of three immunoassay platforms for plasma glial fibrillary acidic protein in Alzheimer's disease.
PubMed 文献 · Clin Chem Lab Med · 2026-04-02

该研究在302例痴呆队列受试者中比较了Simoa HD-X、Maccura i1000和MS-Fast Pro 160三种平台检测血浆GFAP的分析与临床性能。结果显示平台间相关性较强(Spearman r=0.874-0.932),但存在显著比例偏差和绝对浓度差异,各平台鉴别ADD与NADD的AUC相当(0.732-0.740),但最佳截断值差异明显。

要点

  • 三种平台检测血浆GFAP的相关性强,但绝对值和截断值差异显著。
  • 各平台鉴别ADD与NADD的AUC相当(0.732-0.740),但平台特异性截断值不同。
  • Simoa平台上GFAP联合NfL和核心血浆panel可将AUC提升至0.924。

核心结论

  • 三种免疫分析平台检测血浆GFAP相关性较强,但绝对值和决策截断值存在实质性差异,临床鉴别性能相似与平台特异性截断值并存,需进一步 harmonization。

研究设计与样本

  • 研究纳入北京协和医院痴呆队列302例受试者,包括139例阿尔茨海默病痴呆(ADD)和116例非AD痴呆(NADD)。
  • 在Simoa HD-X、Maccura i1000和MS-Fast Pro 160三种免疫分析平台上检测血浆GFAP。
  • 采用Passing-Bablok回归、Bland-Altman分析和Spearman相关性评估平台间一致性。
  • 使用ROC分析和多标志物模型(Simoa平台)评估GFAP、NfL、核心血浆panel(Aβ1-42、p-tau181、p-tau217)及其组合。

主要发现

  • 三种平台检测的血浆GFAP水平在ADD组均显著高于NADD组。
  • 平台间Spearman相关系数为0.874-0.932。
  • Passing-Bablok回归显示存在显著比例偏差,Simoa平台浓度系统性偏高。
  • 各平台鉴别ADD与NADD的ROC曲线AUC为0.732-0.740,但平台特异性最佳截断值差异显著。
  • Simoa平台上GFAP单独鉴别ADD与NADD的AUC为0.731。

关键数值与推荐

  • 平台间Spearman相关系数r=0.874-0.932。
  • 各平台鉴别ADD与NADD的AUC范围为0.732-0.740。
  • Simoa平台GFAP单独AUC为0.731。
  • 核心血浆panel(Aβ1-42、p-tau181、p-tau217)AUC为0.898,联合GFAP和NfL后AUC为0.924。

临床怎么用

  • 血浆GFAP可用于辅助鉴别ADD与NADD,但不同平台检测结果不可直接互换。
  • 临床解读GFAP结果时应使用平台特异性截断值,避免跨平台套用。
  • 联合核心血浆panel及NfL可提升Simoa平台对ADD与NADD的鉴别性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to compare the analytical and clinical performance of plasma glial fibrillary acidic protein (GFAP) across three immunoassay platforms. METHODS: Plasma GFAP was measured on three immunoassay platforms (Simoa HD-X, Maccura i1000, MS-Fast Pro 160) in 302 participants from the Peking Union Medical College Hospital dementia cohort (139 Alzheimer's disease dementia [ADD], 116 non-AD dementia [NADD]). Inter-platform agreement was assessed using Passing-Bablok regression, Bland-Altman analysis, and Spearman correlation. ROC analyses and multimarker models on the Simoa platform were used to evaluate GFAP, NfL, a core plasma panel (Aβ1-42, p-tau181, p-tau217), and their combinations. RESULTS: Plasma GFAP levels were significantly higher in ADD than in NADD across all three platforms. Inter-platform correlations were strong (Spearman's r=0.874-0.932), but Passing-Bablok regression showed substantial proportional bias and systematically higher concentrations on the Simoa platform. ROC-based discrimination between ADD and NADD was comparable across platforms (AUC 0.732-0.740), whereas assay-specific optimal cut-offs differed markedly. On the Simoa platform, GFAP alone achieved an AUC of 0.731. The core plasma panel (Aβ1-42, p-tau181, p-tau217) achieved an AUC of 0.898, which increased to 0.924 after adding GFAP and NfL. CONCLUSIONS: This study provides a comparison of plasma GFAP measurements across three immunoassay platforms, revealing strong correlations but substantial differences in absolute values and decision cut-offs. The clinical analyses show that similar discriminative performance can coexist with markedly different platform-specific cut-offs, underscoring the need for platform-specific cut-offs and further harmonization of GFAP measurements.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Wang Y, Ma X, Zou Y, et al. Comparison of the analytical and clinical performance of three immunoassay platforms for plasma glial fibrillary acidic protein in Alzheimer's disease. Clin Chem Lab Med. 2026. PMID: 41921527. doi:10.1515/cclm-2025-1694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。